Metformin induces distinct bioenergetic and metabolic profiles in sensitive versus resistant high grade serous ovarian cancer and normal fallopian tube secretory epithelial cells

  title={Metformin induces distinct bioenergetic and metabolic profiles in sensitive versus resistant high grade serous ovarian cancer and normal fallopian tube secretory epithelial cells},
  author={M. Hodeib and Martin P. Ogrodzinski and L. Vergnes and K. Reue and B. Karlan and S. Lunt and P. Aspuria},
  pages={4044 - 4060}
Metformin is a widely used agent for the treatment of diabetes and infertility, however, it has been found to have anti-cancer effects in a variety of malignancies including high grade serous ovarian cancer (HGSC). Studies describing the mechanisms by which metformin affects HGSC are ongoing, but detailed analysis of its effect on the cellular metabolism of both HGSC cells and their precursor, normal fallopian tube secretory epithelial cells (FTSECs), is lacking. We addressed the effects of… Expand
Long term treatment of metformin impedes development of chemoresistance by regulating cancer stem cell differentiation through taurine generation in ovarian cancer cells.
Taurine treatment considerably reduced the cancer stem cell population and chemoresistance in resistant cells, indicating a novel role of taurine in differentiation of ovarian cancer stem cells. Expand
Girinimbine Inhibits the Proliferation of Human Ovarian Cancer Cells In Vitro via the Phosphatidylinositol-3-Kinase (PI3K)/Akt and the Mammalian Target of Rapamycin (mTOR) and Wnt/β-Catenin Signaling Pathways
  • Qiu Xin, A. Muer
  • Chemistry, Medicine
  • Medical science monitor : international medical journal of experimental and clinical research
  • 2018
Ginimbine, a carbazole alkaloid used in Chinese herbal medicine, inhibited the proliferation and cell migration of human ovarian cancer cells in vitro, in a dose-dependent manner, via the PI3K/Akt/mTOR and Wnt/β-catenin signaling pathways. Expand
Comparison of the effects of metformin on MDA-MB-231 breast cancer cells in a monolayer culture and in tumor spheroids as a function of nutrient concentrations.
The results show that nutrient availability must be considered when evaluating the effects of metformin in 2D culture and in biologically more relevant 3D tumor spheroids. Expand
Comparison of the effects of metformin on MDA-MB-231 breast cancer cells in a monolayer culture and in tumour spheroids as a function of nutrient concentrations
The main finding is that the effects of metformin on MDA-MB-231 cells depend on in vitro cell model used (monolayer culture vs. tumour spheroids). Expand
Suppression of in vitro and in vivo human ovarian cancer growth by isoacteoside is mediated via sub-G1 cell cycle arrest, ROS generation, and modulation of AKT/PI3K/m-TOR signalling pathway.
It is indicated that isoacteoside has a great potential in suppressing both in vitro and in vivo ovarian cancer cell growth and can be used as a possible anticancer agent. Expand
Pleiotropic Effects of Metformin on Cancer
  • H. Schulten
  • Medicine
  • International journal of molecular sciences
  • 2018
This review emphasizes the pleiotropic effects of MTF and recent progress made in MTF applications in basic, preclinical, and clinical cancer research. Expand
Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors
A mechanistic link between two major cancer hallmarks is shown, which in turn suggests novel possibilities for specifically treating HRD cancers with OXPHOS inhibitors. Expand
Comparison of HepaRG cells following growth in proliferative and differentiated culture conditions reveals distinct bioenergetic profiles
The results support that HepaRG represents an appropriate model to study drug-induced bioenergetic dysfunction and protection against acetaminophen (APAP)-induced cell injury and metformin-induced decreases in bioenergetics in differentiated- but not proliferative-derived Hepa RG. Expand
From old to new - Repurposing drugs to target mitochondrial energy metabolism in cancer.
This review article summarizes current concepts and therapeutic opportunities in the area of targeting aerobic mitochondrial energy metabolism in cancer by considering only those drugs which predominantly inhibit oxidative phosphorylation. Expand


Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells
Assessment of metabolic changes induced by metformin and phenformin in an Src-inducible model of cellular transformation and in mammosphere-derived breast CSCs shows that the metabolic profiles are consistent with the idea that biguanides inhibit mitochondrial complex 1, but they indicate that their metabolic effects differ depending on the stage of cellular Transformation. Expand
Metformin Antagonizes Cancer Cell Proliferation by Suppressing Mitochondrial-Dependent Biosynthesis
It is demonstrated that the metabolic checkpoint kinases AMP-activated protein kinase (AMPK) and LKB1 are not required for the antiproliferative effects of metformin, and that metabolic adaptations that bypass mitochondrial-dependent biosynthesis may provide a mechanism of tumor cell resistance to biguanide activity. Expand
Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer
It is indicated that hyperglycemia inhibits the anti-cancer effects of metformin in vitro and in vivo, and the results suggest that meetformin may elicit stronger responses in normoglycemic vs. hyperglycemic patients, highlighting the need for prospective clinical testing in patients without diabetes. Expand
Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis
In human cancer cells, metformin inhibits mitochondrial complex I (NADH dehydrogenase) activity and cellular respiration, indicating that cancer cells rely exclusively on glycolysis for survival in the presence of meetformin. Expand
Metformin Targets Central Carbon Metabolism and Reveals Mitochondrial Requirements in Human Cancers.
An integrative metabolomics analysis of metformin action in ovarian cancer demonstrates with stable isotope tracing that a metabolic signature obtained from a patient with an exceptional clinical outcome mirrored that of a responsive animal tumor. Expand
Metformin directly acts on mitochondria to alter cellular bioenergetics
It is demonstrated that metformin directly acts on mitochondria to limit respiration and that the sensitivity of cells to meetformin is dependent on their ability to cope with energetic stress. Expand
Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1.
RedD1 (also known as DDIT4 and RTP801), a negative regulator of mTOR, is identified as a new molecular target of metformin and inhibition of REDD1 reverses meetformin-induced cell-cycle arrest and significantly protects from the deleterious effects of met formin on cell transformation. Expand
Metformin targets ovarian cancer stem cells in vitro and in vivo.
The results of this study provide a rationale for using metformin to treat ovarian cancer patients because it can restrict the growth and proliferation of ovarian cancer stem cells in vitro and in vivo. Expand
Mechanism of Metformin-dependent Inhibition of Mammalian Target of Rapamycin (mTOR) and Ras Activity in Pancreatic Cancer
The antineoplastic activities of metformin in pancreatic cancer are due, in part, to down-regulation of Sp TFs and Sp-regulated IGF-1R and EGFR, which in turn results in inhibition of mTOR and Ras signaling, respectively. Expand
Metformin—mode of action and clinical implications for diabetes and cancer
The updated understanding of the antigluconeogenic action of met formin in the liver and the implications of the discoveries of metformin targets for the treatment of diabetes mellitus and cancer are discussed. Expand